Table 2.

Characteristics of the cohort of patients undergoing belatacept therapy and matched controls

Characteristics	Belatacept (n = 27)			Matched controls (n = 54)			P value
	N/A	No.	%	N/A	No.	%
Positive serology after 2 doses	12	2	13.3	24	8	25.8	0.45
Positive serology after 3 doses	0	6	22.2	0	32	59.7	0.01
Male recipient	0	16	59.2	0	38	70.3	0.33
Transplant rank ≥2a	0	4	14.8	0	15	38.4	0.26
Calcineurin inhibitor treatment	0	7	25.9	0	37	68.5	<0.001
mTOR inhibitor treatment	0	0	0	0	12	22.2	0.006
Antimetabolite treatment	0	18	66.7	0	36	66.7	1
Steroid treatment	0	19	70.3	0	38	70.3	1

	N/A	Mean	SD	N/A	Mean	SD	P value
Age, yr	0	61.2	14.2	0	60.9	13.9	0.91
Time from transplantation, yr	0	4.4	3.9	0	7.4	7.8	0.27
Lymphocyte count, /mm3	0	1257	660	0	1450	958	0.57
Anti-spike IgG titer after 3 doses, BAU/ml	0	24.5	69.6	0	106.5	116.4	<0.001
Allograft function by MDRD, ml/min	0	34.7	12.5	0	45.6	20.6	0.02

BAU, binding antibody unit; MDRD, Modification of Diet in Renal Disease; N/A, nonavailable data.

^aTransplant rank ≥2: patient having received a second or more transplant kidney.